Compare ACADIA Pharmaceuticals Inc. (ACAD) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs EHang Holdings Ltd - ADR — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.5 (market cap $5.07B), while EHang Holdings Ltd - ADR trades at $5.68 (market cap $437.63M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 11.6× EHang Holdings Ltd - ADR's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| ACAD | EH | |
|---|---|---|
Market Cap | $5.07B | $437.63M |
Sector | Health | Industrials |
52-Week High | $29.41 | $19.44 |
52-Week Low | $20.06 | $4.90 |
Enterprise Value | $4.19B | $376.84M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
EHang Holdings (EH) trades at $5.66, down 0.53% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, but net losses persist with a margin of -77.57%. Recent news includes the successful pilotless eVTOL flight in Kazakhstan, highlighting operational progress amid financial challenges.
The stock presents high-risk potential with analyst consensus divided and a price target of $6.97. Investment appeal hinges on commercialization success and cost management, but substantial losses and competitive pressures pose significant risks to near-term shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
